News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Estela Rodriguez: The second-line options for EGFR lung cancer beyond platinum-chemo after best therapies upfront
Estela Rodriguez/X
Apr 15, 2025, 07:40

Estela Rodriguez: The second-line options for EGFR lung cancer beyond platinum-chemo after best therapies upfront

Estela Rodriguez, Associate Director, Community Outreach of Thoracic Oncology at Sylvester Comprehensive Cancer Center , shared a post on X:

“If we move our best therapies upfront, what are the 2nd line options for EGFR lung cancer beyond platinum-chemo?

  • amivantamab+chemo
  • ivonescimab+chemo
  • ADCs: DatoDxd, PatritumabDxd.”

Estela Rodriguez: The second-line options for EGFR lung cancer beyond platinum-chemo after best therapies upfront

More posts featuring TexasLung25.

cancer Estela Rodriguez Lung cancer OncoDaily Oncology Rachel E. Sanborn TexasLung25
Special Coverage
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma
Blog
Jun 19, 2025, 15:15
Antonio Jimenez Jimenez Shared Findings from the Multicenter ACCESS trial, Supported by CIBMTR and NMDP